Skip to content
AlternativeMed

SPECIALTY TOPICS · GUIDE

Extracellular Vesicles and Exosomes: Research Overview

What extracellular vesicles and exosomes are, why the words are used loosely, what trials exist, and why no exosome product is FDA-approved in the United States.

Content last updated . This page has not been medically reviewed.

Back to Emerging Wellness Science
Quick answer
Extracellular vesicles (EVs) are tiny packages that cells release. They are a real and active research field. Most evidence about using them as treatments comes from cells and animals, and no exosome product is FDA-approved in the United States. This page is information only, not medical advice.

What they are

EVs are particles wrapped in a fat-based membrane that cells release naturally. They carry proteins, fats and genetic material from one cell to another. [1] [2] "Exosome" is one type of EV, defined by how it forms inside the cell. In aesthetic medicine, though, many products and studies call their preparations "exosomes" even when that origin has not been shown. [2]

Keeping words apart matters here:

  • Field: EV biology, the study of these particles.
  • Mechanism: the idea that EVs pass signals between cells.
  • Product: a specific preparation sold or tested, with a source, a method of separation and a measured content.
  • Claim: what a seller says that preparation does.

A finding about the first two does not support the fourth. See mechanism vs demonstrated benefit.

Why measurement is hard

The International Society for Extracellular Vesicles publishes guidance on the minimum information a study should report. Its 2023 update says the field still faces challenges in naming, in separating EVs from non-vesicular particles, and in characterizing what was isolated. [3] A correction to that document was later published. [4] If researchers struggle to say exactly what is in a preparation, a buyer cannot tell either.

What the clinical trial record looks like

A 2024 systematic review of public trial registries found 471 EV-related clinical trials. Most were about diagnostics, with cancer the most frequent area. The treatment trials mainly used EVs from mesenchymal stromal cells, most often for breathing-related illness. Isolation methods were often not reported in the trial records. [5] A registered trial shows that research is happening. It does not show that the treatment works.

A 2025 review of EV-based drugs described obstacles in understanding the mechanism, manufacturing, quality control and nonclinical testing, and reported that no drug regulator had issued EV-specific technical guidelines at the time of writing. [6] An erratum to that review was published in 2026, so check the current version.

Evidence level by use

4 findings · 2 supported · 2 limited or unclearThe colour follows the evidence label on each card.

  1. EVs as laboratory research tools and biomarkers

    Established as a research field

    Standards still developing [3]

  2. EVs from stem-like cells as treatments (any condition)

    Preclinical for most uses; early human studies for some

    See the skin, wound and hair pages below

  3. Wound healing and scars (placental-cell exosomes)

    Preclinical (cells/animals only) for the meta-analyzed data; human data limited

    A 2026 meta-analysis pooled 21 animal studies; human evidence was early-phase trials, case series and observational studies [7]

  4. Skin and hair (aesthetic)

    Promising but limited, with large uncertainty

    See laboratory findings vs marketed exosome products

Related guides

Frequently asked questions

Are exosomes and extracellular vesicles the same thing?

Exosomes are one type of extracellular vesicle. Many aesthetic products and studies use "exosome" loosely, even when the origin has not been shown. [2]

Are exosome treatments FDA-approved?

The FDA states there are currently no FDA-approved exosome products. [9] Its consumer alert says the same for products intended to treat disease. [8]

Does a registered trial mean an exosome therapy works?

No. A review of 471 registered EV trials found most were diagnostic, and isolation methods were often not reported. [5]

Have exosome products caused harm?

The FDA reported serious adverse events in Nebraska patients treated with unapproved products marketed as containing exosomes. [9]

Can I rely on animal results?

No. Cell and animal findings are preclinical. In a 2026 meta-analysis of placental-cell exosomes, the pooled data were from 323 animals and human evidence was early. [7]

More details: evidence, limits and cautions

The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.

Regulation in the United States
The FDA says exosome products intended to treat diseases or conditions in humans generally require FDA approval, and that there are currently no FDA-approved exosome products. [8] Its 2019 safety notification followed reports of serious adverse events in Nebraska patients treated with unapproved products marketed as containing exosomes. [9] Other countries have their own rules, and the FDA says it does not oversee treatments done abroad. [9] This is not legal advice, and rules change.
Risks
The FDA has linked unapproved exosome products to serious adverse events. [9] A 2026 review also notes reports of adverse reactions tied to unapproved products sold as exosome-based. [2] Because contents are poorly defined, risks cannot be predicted for a given product.
Who should check first
Anyone offered an "exosome" treatment should ask which exact product it is, whether the FDA has reviewed it under an investigational application, and what human trials support it. The FDA suggests asking for the IND number and reading the consent form. [9] Report problems to the FDA's MedWatch program. [8]
References
  1. The therapeutic and commercial landscape of stem cell vesicles in regenerative dermatology. J Control Release 2023. PubMed 36535543. Read 2026-10-22.
  2. Extracellular Vesicles in Regenerative and Cosmetic Medicine. Int J Mol Sci 2026. PubMed 42353255. Read 2026-10-22.
  3. Welsh JA, et al. Minimal information for studies of extracellular vesicles (MISEV2023). J Extracell Vesicles 2024. PubMed 38326288. Read 2026-10-22.
  4. Correction to "Minimal information for studies of extracellular vesicles (MISEV2023)". J Extracell Vesicles 2024. PubMed 38726651. Read 2026-10-22.
  5. A critical systematic review of extracellular vesicle clinical trials. J Extracell Vesicles 2024. PubMed 39330928. Read 2026-10-22.
  6. Extracellular vesicle-based drug overview. Signal Transduct Target Ther 2025. PubMed 40804047. Read 2026-10-22.
  7. Human Placental MSC-Derived Exosomes in Wound Healing and Scar Therapy: Systematic Review and Meta-analysis. Aesthet Surg J 2026. PubMed 41800724. Read 2026-10-22.
  8. U.S. Food and Drug Administration. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. Read 2026-10-22.
  9. U.S. Food and Drug Administration. Public Safety Notification on Exosome Products (December 6, 2019). Read 2026-10-22.
Education, not medical advice. This page is for general information. It does not diagnose or treat any condition and is not a substitute for care from a qualified health professional. Natural does not automatically mean safe. Ask a clinician or pharmacist before changing your care, especially if you take medication, are pregnant or breastfeeding, or have a health condition.